The effects of Somin-On for cognition support in older adults were assessed in a recently published study.
Image | adobe.stock/Alexandra
In an April 23, 2025, press release, Arjuna Natural announced it would showcase its ashwagandha extract at Vitafoods Europe 2025, highlighting recent research demonstrating its potential for supporting memory in adults with mild cognitive impairment (MCI). The extract, Somin-On, is standardized to a 2% content Sominone and is formulated to support multiple cognitive functions. Somin-On was developed as a sequel to Shoden, Arjuna’s original ashwaghanda extract, which was designed for stress relief and sleep support.
“Our new ashwagandha formulation was developed in direct response to the rising concerns of cognitive decline among today’s aging population,” stated Benny Antony, PhD, joint managing director of Arjuna Natural, in the press release. “This group is actively seeking natural solutions to maintain mental clarity and focus, and help prevent any potential onset of dementia as its members age. Somin-On offers a promising, safe and natural approach for supporting brain function helping older adults stay sharp and mentally agile.”
In a randomized double-blind, placebo-controlled pilot study1 published in March 2025, 40 participants were given either Somin-On (250 mg daily) or a placebo, with cognitive assessments performed at 30 and 60 days after the start of the trial.
Highlighted results from the study include:
“Sominone, derived from Withania somnifera, is identified as the main active metabolite responsible for these specific effects,” explained Antony. “Ashwagandha is a traditional Ayurvedic herb that has been widely used for centuries to manage stress and anxiety, and cognitive support function. This compound has been identified and extensively analyzed for its potential benefits in enhancing memory and cognitive functions.”
Arjuna will be at Booth 4J2 at Vitafoods Europe, taking place May 20-22 in Barcelona, Spain.
Reference